In conclusion, the significant elevation of HE4, an ovarian cancer marker, in malignant breast tumor patients and its non elevation in benign breast tumor patients makes it an interesting and important biomarker in the evaluation of breast tumors, in addition to the current markers. This evidence concerns the gene WFDC2 and breast cancer.